Adjuvant pembrolizumab for NSCLC
Individuals diagnosed with oligometastatic NSCLC can benefit from local ablative therapy, though the impact of adjuvant systemic treatment is uncertain. During the poster session at ASCO 2023, Dr. David Cantor from Penn Medicine at the University of Pennsylvania in Philadelphia, USA presented the long-term results of a single-arm phase II clinical trial. The study offered one year of pembrolizumab after local ablative therapy to these patients, examining their progression-free survival and overall survival.
With the educational support of:
